Due to the special nature of medicines, returns and exchanges are not supported.
Final delivery from the nearest overseas warehous NEW

Nirmatrelvir Tablets/Ritonavir Tablets

Effects and efficacy: This product is suitable for use in combination with other antiretroviral drugs to treat human immunodeficiency virus type 1 (HIV-1) infection in adults and children over 2 years old.
Dosage and administration:
Adults: The recommended dose is 2 tablets twice a day. This product can be taken with or without food. When combined with efavirenz, nevirapine, amprenavir, Fosampre, fosamprenavir or nelfinavir, the recommended dose of this product (2 tablets once, twice a day) can be used in combination with the above drugs without adjusting the dose. Children: Children with a body weight of >40kg or a body surface area BSA = {[height (cm) × weight (kg)]/3600} greater than 1.3m, can use the recommended adult dose (2 tablets once, twice a day); children with a body weight of <40kg or a body surface area (BSA) less than 1.3m are recommended to use a child's dose of lopinavir-ritonavir oral solution. Adverse Reactions: The most common adverse reactions associated with treatment with budesonide during clinical trials were diarrhea, nausea, vomiting, hypertriglyceridemia, and hypercholesterolemia. Patients taking budesonide once daily may be at greater risk for diarrhea. Diarrhea, nausea, and vomiting may occur at the start of treatment, and hypertriglyceridemia and hypercholesterolemia may occur later. In Phase II-IV trials, 7% of subjects withdrew from the study prematurely due to adverse events during treatment. Cushing's syndrome has been reported in patients receiving ritonavir and inhaled or intranasal fluticasone propionate; this may also occur with other corticosteroids metabolized by P4503A (budesonide). Increased creatine phosphokinase (CPK), myalgia, myositis, and rhabdomyolysis (rarely) have been reported with the use of protease inhibitors, especially in combination with nucleoside reverse transcriptase inhibitors. HIV patients treated with combined antiretroviral therapy experience redistribution of body fat (lipodystrophy), including loss of peripheral and facial subcutaneous fat, increased intra-abdominal and visceral fat, breast enlargement, and fat accumulation on the back of the neck (buffalo hump). Combined antiretroviral therapy can cause metabolic abnormalities such as hypertriglyceridemia, hypercholesterolemia, insulin resistance, hyperglycemia, and hyperlactatemia. HIV patients who are already severely immunocompromised when starting combined antiretroviral therapy (CART) may experience asymptomatic infection or inflammatory reactions caused by residual opportunistic infections. Cases of osteonecrosis have been reported, especially in patients with recognized risk factors, patients with advanced AIDS, or patients receiving combined antiretroviral therapy (CART) for a long time. Its frequency is unknown. Contraindications: Allergy to this product is contraindicated. Contraindicated in patients with liver damage. Use with caution during lactation. Use with caution in patients with hepatic and renal insufficiency.


Featured products

Laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor.